Ⅲ期非小细胞肺癌肺切除术后的生存情况
Survival after Pneumonectomy for Stage III Non-small Cell Lung Cancer.
作者信息
Saha Sibu P, Kalathiya Rohan J, Davenport Daniel L, Ferraris Victor A, Mullett Timothy W, Zwischenberger Joseph B
机构信息
Department of Surgery, University of Kentucky, Lexington, KY.
Johns Hopkins General Surgery Residency Program; Baltimore, MD.
出版信息
Oman Med J. 2014 Jan;29(1):24-7. doi: 10.5001/omj.2014.06.
OBJECTIVES
Stage III non-small cell lung cancer (NSCLC) has a poor prognosis. Reports suggest that five-year survival after current treatment is between 14 to 24 percent. The purpose of this retrospective study was to investigate the morbidity and mortality of patients diagnosed with stage III NSCLC and treated with pneumonectomy at the University of Kentucky Medical Center in Lexington, KY.
METHODS
We reviewed the medical record and tumor registry follow-up data on 100 consecutive patients who underwent pneumonectomy for lung cancer at the University of Kentucky.
RESULTS
We identified thirty-six patients in stage III who underwent pneumonectomy. Ten patients had surgery only, eight patients received adjuvant chemotherapy, and eighteen patients received neoadjuvant therapy. There was one surgical death in this series. Mean follow-up was 2.9 years. One-, three-, and five-year survival was 66%, 38%, and 38%, respectively. Five-year survival for the group with adjuvant therapy was 60%.
CONCLUSION
Most lung cancer patients present with advanced disease and the prognosis remains poor. Our experience indicates resection offers an above average chance of long-term survival when supplemented with neoadjuvant and/or adjuvant therapy.
目的
Ⅲ期非小细胞肺癌（NSCLC）预后较差。报告显示，目前治疗后的五年生存率在14%至24%之间。这项回顾性研究的目的是调查在肯塔基州列克星敦市肯塔基大学医学中心被诊断为Ⅲ期NSCLC并接受肺切除术治疗的患者的发病率和死亡率。
方法
我们回顾了肯塔基大学100例连续接受肺癌肺切除术患者的病历和肿瘤登记随访数据。
结果
我们确定了36例接受肺切除术的Ⅲ期患者。10例患者仅接受手术，8例患者接受辅助化疗，18例患者接受新辅助治疗。该系列中有1例手术死亡。平均随访时间为2.9年。1年、3年和5年生存率分别为66%、38%和38%。接受辅助治疗组的5年生存率为60%。
结论
大多数肺癌患者就诊时已处于晚期，预后仍然较差。我们的经验表明，在新辅助和/或辅助治疗的辅助下，手术切除提供了高于平均水平的长期生存机会。
Zotero 插件